CYRX - Bathi resik saben saham (EPS TTM) Cryoport Systems

Cryoport, Inc. (CYRX) dominates the IT logistics niche for gene therapy by integrating Cryoportal software into the processes of pharmaceutical behemoths. The TTM net income per share snapshot visualizes the financial dynamics, where the -0.90 metric determines this level. Revenues are based on cryogenic equipment and biomaterial monitoring, while strict industry regulatory standards ensure high margin protection and business resilience.

Steady demand for live cell logistics provides Cryoport, Inc. (CYRX) with a consistent flow of operating liquidity, cementing the issuer's status as a reliable industry player. This metric calculates the total earnings per common share per year, allowing investors to assess the actual efficiency of capitalization. Analyzing the company's TTM net income per share helps filter out market noise and avoid overpaying for the asset.